companyName

extensiveId

feedTypes

includeDividend

includeEstimates

includeOverview

includeOwnership

includeResearchContent

researchId

snapshotDate

CompanyName_Query

companySlug

CompanyMetaData

Company_query

company

query CompanyName_Query(
  $companyName: String!
  $extensiveId: ID
  $snapshotDate: String
  $researchId: ID
  $includeResearchContent: Boolean!
  $feedTypes: [ContentType!]!
  $includeEstimates: Boolean!
  $includeOverview: Boolean!
  $includeOwnership: Boolean!
  $includeDividend: Boolean!
) {
  ...CompanyMetaData_Ux1x9
  ...Company_query_1TiJKa
}

fragment AnalystData on Analyst {
  name
  pageUrl
  jobTitle
  imgUrl
}

fragment AuthorList on Content {
  __isContent: __typename
  id
  authors {
    __typename
    id
    name
    pageUrl
  }
}

fragment ChangePercentBlock_Company on Company {
  defaultInstrument {
    isin
    symbol
    priceData {
      diff1mPercentage
      diff1yPercentage
      diff3yPercentage
      diffFromStartPercentage
    }
    id
  }
}

fragment CompactFeed_3NXCcw on Query {
  compactFeed: feedContent(companySlug: $companyName, filter: {types: $feedTypes}) {
    edges {
      node {
        __typename
        id
        ...TeaserExtraCompact_content
        createdAt
        companies {
          viewerIsFollowing
          id
        }
      }
      cursor
    }
    pageInfo {
      endCursor
      hasNextPage
    }
  }
}

fragment CompanyAnalystQuery on Company {
  analysts {
    ...AnalystData
    name
    pageUrl
    jobTitle
    imgUrl
    id
  }
}

fragment CompanyCoverage_Company on Company {
  analysts {
    name
    id
  }
  isPayingCustomerOf
  isFormerCustomerOf
  isCorporateCustomer
  ...CompanyAnalystQuery
  defaultInstrument {
    ...TargetAndRecommendation_Company
    id
  }
}

fragment CompanyDescription_Company on Company {
  description
  websiteUrl
  name
}

fragment CompanyDisclaimer_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    isPayingCustomerOf
    isFormerCustomerOf
    id
  }
}

fragment CompanyDividendER_query on Company {
  name
  defaultInstrument {
    estimateData {
      reportingCurrency
    }
    dividendTransactions: estimateTransactions(first: 1, includeQuarters: false) {
      actualized {
        year
        dividend
        dividendYield
        payoutPercentage
        sharePrice
      }
      estimates {
        year
        dividend
        dividendYield
        payoutPercentage
        sharePrice
      }
    }
    id
  }
}

fragment CompanyDividendNonER_query on Company {
  name
  defaultInstrument {
    nonERDividendSet: nonERCompanyNumberSet(includeQuarters: false) {
      year
      dividend
      dividendYield
      epsReported
      sharePrice
      currency
    }
    id
  }
}

fragment CompanyDividend_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    ...CompanyDividendER_query
    ...CompanyDividendNonER_query
    defaultInstrument {
      coreId
      id
    }
    id
  }
}

fragment CompanyFinancials_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    ...NonERCompanyNumbers_query
    ...CompanyNumbers_query
    defaultInstrument {
      coreId
      id
    }
    id
  }
}

fragment CompanyHeader_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    id
    companyInsref
    name
    viewerIsFollowing
    followersCount
    isCorporateCustomer
    hasPinpointData
    hasDividendHistory
    sector {
      sectorname
      industry
    }
    regions
    extensiveExists
    researchContentExists
    defaultInstrument {
      symbol
      priceData {
        tradeCurrency
        lastPrice
        diff1dPercentage
      }
      marketplace {
        name
      }
      estimates: estimateTransactions(first: 1, includeQuarters: false) {
        date
      }
      nonERCompanyNumberSet(first: 1, includeQuarters: false) {
        year
      }
      id
    }
    topOwners {
      holders {
        name
      }
    }
    transactions: insiderTransactions(filter: {types: [BUY, SELL, SUBSCRIPTION]}) {
      edges {
        node {
          date
          id
        }
      }
    }
  }
}

fragment CompanyInsiderTransactions on Company {
  name
  regions
  insiderTransactions(filter: {types: [BUY, EXERCISE_OF_SHARE_OPTION, PLEDGE, RECEPTION_OF_SHARE_PREMIUM, SELL, SUBSCRIPTION]}) {
    edges {
      node {
        insider
        position
        volume
        price
        date
        unit
        type
        relatedParty
        id
      }
    }
  }
}

fragment CompanyInvestorConsensus_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    companyInsref
    id
  }
}

fragment CompanyMetaData_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    description
    pageUrl
    defaultInstrument {
      estimateData {
        modelType
      }
      id
    }
    id
  }
}

fragment CompanyName_Slug on Company {
  slug
}

fragment CompanyNumbers_query on Company {
  name
  defaultInstrument {
    estimateData {
      modelType
      reportingCurrency
    }
    estimateTransactions(first: 1, includeQuarters: true) {
      comparisonIndexName
      actualized {
        year
        quarter
        revenue
        revenueGrowth
        ebitda
        ebitAdjusted
        ebitReported
        preTaxProfit
        netEarnings
        epsReported
        epsAdjusted
        dividend
        payoutPercentage
        roePercent
        roiPercent
        enterpriseValue
        bookValue
        marketCap
        gearingPercent
        equityRatio
        dividendYield
        totalCosts
        loanLosses
        balanceSheetTotal
        tangibleBook
        cet1
        rwa
        sharePrice
        sharesTotal
        nav
        navPerShare
        opexOfNav
        totalShareholderReturn
        comparisonIndexReturn
        netDebtTotalAsset
        quarterlySharePrice
      }
      estimates {
        year
        quarter
        revenue
        revenueGrowth
        ebitda
        ebitAdjusted
        ebitReported
        preTaxProfit
        netEarnings
        epsReported
        epsAdjusted
        dividend
        payoutPercentage
        roePercent
        roiPercent
        enterpriseValue
        bookValue
        marketCap
        gearingPercent
        equityRatio
        dividendYield
        totalCosts
        loanLosses
        balanceSheetTotal
        tangibleBook
        cet1
        rwa
        sharePrice
        sharesTotal
        nav
        navPerShare
        opexOfNav
        totalShareholderReturn
        comparisonIndexReturn
        netDebtTotalAsset
        quarterlySharePrice
      }
    }
    id
  }
}

fragment CompanyOverviewGraphs_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      companyTransactions: estimateTransactions(first: 1, includeQuarters: false) {
        actualized {
          year
          revenue
          ebitAdjusted
          epsAdjusted
          dividendYield
          navPerShare
          totalShareholderReturn
        }
        estimates {
          year
          revenue
          ebitAdjusted
          epsAdjusted
          dividendYield
          navPerShare
          totalShareholderReturn
        }
      }
      id
    }
    id
  }
}

fragment CompanyOwners on Company {
  regions
  topOwners {
    recordDate
    compareDate
    source
    holders {
      name
      capitalPercent
      votingPowerPercent
      totalShares
      positionChange
      totalSharesChange
      shareChange
      isNew
      isRemoved
    }
  }
}

fragment CompanyOwnership_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    ...CompanyOwners
    ...CompanyInsiderTransactions
    id
  }
}

fragment CompanyPageBottom_query_2bVJwf on Query {
  ...GeneralFeed_data_3NXCcw
  ...CompactFeed_3NXCcw
  ...UpcomingEventsQuery_Ux1x9
  ...RiskRecommendMatrix_query_Ux1x9
  ...CompanyOverviewGraphs_query_Ux1x9
  ...NonERCompanyOverviewGraphs_query_Ux1x9
  company(companySlug: $companyName) {
    companyInsref
    ...ForumUpdates_Company
    defaultInstrument {
      coreId
      id
    }
    id
  }
  allFeed: feedContent(first: 1, companySlug: $companyName, filter: {hideUpcomingVideos: true}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  main: feedContent(first: 1, companySlug: $companyName, filter: {hideUpcomingVideos: true, types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT, ANALYST_COMMENT, VIDEO, ARTICLE]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  webcasts: feedContent(first: 1, companySlug: $companyName, filter: {hideUpcomingVideos: true, types: [WEBCAST]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  thirdPartyResearch: feedContent(first: 1, companySlug: $companyName, filter: {types: [THIRD_PARTY_COMPANY_REPORT]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  releases: feedContent(first: 1, companySlug: $companyName, filter: {types: [STOCK_EXCHANGE_RELEASE, PRESS_RELEASE]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
}

fragment CompanyPageTop_query_Ux1x9 on Query {
  ...StockChart_ChartQuery_Ux1x9
  ...LatestReports_query_Ux1x9
  company(companySlug: $companyName) {
    isFund
    name
    ...CompanyCoverage_Company
    ...CompanyName_Slug
    ...CompanyDescription_Company
    ...FundNumbers_Company
    ...ChangePercentBlock_Company
    ...KeyEstimateFigures_Company
    ...InvestmentCompanyKeyFigures_Company
    defaultInstrument {
      id
      estimateData {
        modelType
      }
    }
    analysts {
      name
      id
    }
    id
  }
  extensiveReport: feedContent(first: 1, companySlug: $companyName, filter: {types: [EXTENSIVE_COMPANY_REPORT]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  analysis: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku", "Arvonluojat"]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  analysisArvonluojat: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku"]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment Company_query_1TiJKa on Query {
  ...CompanyHeader_query_Ux1x9
  ...CompanyOwnership_query_Ux1x9 @include(if: $includeOwnership)
  ...CompanyFinancials_query_Ux1x9 @include(if: $includeEstimates)
  ...CompanyDividend_query_Ux1x9 @include(if: $includeDividend)
  ...CompanyInvestorConsensus_query_Ux1x9
  ...CompanyPageTop_query_Ux1x9 @include(if: $includeOverview)
  ...CompanyPageBottom_query_2bVJwf @include(if: $includeOverview)
  ...CompanyDisclaimer_query_Ux1x9
  ...Extensive_query_3u4Ry5
  ...ResearchContent_query_14bL89
}

fragment Extensive_query_3u4Ry5 on Query {
  company(companySlug: $companyName) {
    extensive(extensiveId: $extensiveId, snapshotDate: $snapshotDate) {
      publishedAt
      pageUrl
      pdfUrl
      content {
        id
        title
        lang
        slug
        htmlBody
        publishedAt
        createdAt
        changedAt
        isOutdated
      }
    }
    id
  }
}

fragment ForumUpdates_Company on Company {
  name
  forum {
    threadUrl
    highlightedPosts {
      url
      author
      authorImgUrl
      text
      postedAt
      likesCount
    }
  }
}

fragment FundNumbers_Company on Company {
  defaultInstrument {
    isin
    symbol
    priceData {
      lastPrice
      ath
    }
    id
  }
}

fragment GeneralFeed_data_3NXCcw on Query {
  generalFeed: feedContent(first: 20, companySlug: $companyName, filter: {types: $feedTypes}) {
    edges {
      node {
        __typename
        id
        companies {
          name
          id
        }
        ...Teaser_content
        ...TeaserCompact_content
      }
      cursor
    }
    pageInfo {
      endCursor
      hasNextPage
    }
  }
}

fragment InvestmentCompanyKeyFigures_Company on Company {
  marketData {
    marketCap
  }
  defaultInstrument {
    priceData {
      tradeCurrency
      dailyTurnover
    }
    estimateData {
      modelType
    }
    estimateTransactions(first: 1, includeQuarters: true) {
      actualized {
        year
        quarter
        sharesTotal
        marketCap
        nav
        navPerShare
        dividendYield
        quarterlySharePrice
      }
      estimates {
        year
        quarter
        dividendYield
      }
    }
    id
  }
}

fragment KeyEstimateFigures_Company on Company {
  marketData {
    marketCap
  }
  defaultInstrument {
    priceData {
      tradeCurrency
      dailyTurnover
      lastPrice
      marketCap
    }
    sector
    fundamentalData {
      ebit
      eps
      sales
      dividend
    }
    estimateData {
      modelType
      estimates {
        firstEstimateYear {
          year
          bookValue
          netSales
          dividendA
          epsAdjusted
          ebitAdjusted
          hybridLoan
          noOfShares
          netDebt
          mvMinorities
          mvAssociated
          roePercent
        }
      }
    }
    estimatesSharePrice: estimateTransactions(first: 1) {
      estimates {
        sharePrice
      }
    }
    id
  }
}

fragment LatestReports_query_Ux1x9 on Query {
  extensiveReport: feedContent(first: 1, companySlug: $companyName, filter: {types: [EXTENSIVE_COMPANY_REPORT]}) {
    edges {
      node {
        __typename
        createdAt
        pageUrl
        id
      }
    }
  }
  analysis: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku", "Arvonluojat"]}) {
    edges {
      node {
        __typename
        createdAt
        pageUrl
        id
      }
    }
  }
  analysisArvonluojat: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku"]}) {
    edges {
      node {
        __typename
        createdAt
        pageUrl
        id
      }
    }
  }
}

fragment NonERCompanyNumbers_query on Company {
  name
  defaultInstrument {
    nonERNumberSet: nonERCompanyNumberSet(includeQuarters: true) {
      year
      quarter
      revenue
      ebitda
      ebitReported
      epsReported
      dividend
      sharesTotal
      roe
      roi
      enterpriseValue
      marketCap
      gearingRatio
      equityRatio
      dividendYield
      sharePrice
      currency
      evSales
      evEbitda
      evEbit
      pb
      netIncome
      ptp
    }
    id
  }
}

fragment NonERCompanyOverviewGraphs_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      overviewGraphsData: nonERCompanyNumberSet(includeQuarters: false) {
        year
        revenue
        ebitReported
        epsReported
        dividend
        dividendYield
        currency
      }
      id
    }
    id
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ResearchContent_query_14bL89 on Query {
  company(companySlug: $companyName) {
    slug
    researchContentFeed @include(if: $includeResearchContent) {
      __typename
      id
      ...Teaser_content
    }
    researchContentIds @include(if: $includeResearchContent)
    researchContent(researchId: $researchId) @include(if: $includeResearchContent) {
      researchId
      researchTitle
      publishedAt
      pageUrl
      content {
        id
        title
        lang
        slug
        htmlBody
        publishedAt
        createdAt
        changedAt
        isOutdated
      }
    }
    id
  }
}

fragment RiskRecommendMatrix_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      riskData: estimateTransactions(first: 1) {
        businessRisk
        valuationRisk
      }
      id
    }
    id
  }
}

fragment StockChart_ChartQuery_Ux1x9 on Query {
  company(companySlug: $companyName) {
    isFund
    defaultInstrument {
      coreId
      id
      marketOpen
      marketClose
      marketplace {
        region
      }
      priceData {
        lastPrice
      }
      returns {
        day
        week
        month
        threeMonths
        sixMonths
        year
        threeYears
        fiveYears
        tenYears
        ytd
        total
      }
    }
    id
  }
}

fragment TargetAndRecommendation_Company on Instrument {
  estimateData {
    modelType
    researchCurrency
    estimates {
      date
      recommendation
      targetPrice
    }
  }
}

fragment TeaserCompact_content on Content {
  __isContent: __typename
  __typename
  id
  type
  title
  createdAt
  isPremium
  pageUrl
  lang
  companies {
    ...CompanyTagList
    id
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
  ...AuthorList
}

fragment TeaserExtraCompact_content on Content {
  __isContent: __typename
  id
  title
  createdAt
  pageUrl
  lang
  companies {
    name
    pageUrl
    viewerIsFollowing
    id
  }
}

fragment Teaser_content on Content {
  __isContent: __typename
  __typename
  id
  type
  title
  createdAt
  pageUrl
  imgUrl
  isPremium
  lang
  companies {
    ...CompanyTagList
    id
  }
  publishers {
    imgUrl
  }
  authors {
    __typename
    id
  }
  ... on AnalystComment {
    preview
  }
  ... on Article {
    preview
  }
  ... on CompanyReport {
    preview
  }
  ... on ThirdPartyCompanyReport {
    preview
  }
  ... on QA {
    preview
  }
  ... on Video {
    preview
    liveTime
    videoDuration
  }
  ... on Webcast {
    preview
    liveTime
  }
  ...AuthorList
  ...Reactions
}

fragment UpcomingEventsQuery_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      calendarEvents(first: 10) {
        edges {
          node {
            date
            type
            period
            id
          }
        }
      }
      id
    }
    id
  }
}


name

description

pageUrl

defaultInstrument

companyInsref

viewerIsFollowing

followersCount

isCorporateCustomer

hasPinpointData

hasDividendHistory

sector

regions

extensiveExists

researchContentExists

topOwners

insiderTransactions

isPayingCustomerOf

isFormerCustomerOf

extensive

slug

feedContent

Physitrack

Physitrack Plc Lands New Deal with UK NHS Trust

Redeye: Physitrack (Q1 Review): Enters a new growth phase

Redeye: Physitrack (Q1 Interview): Growth pivot starts here; RTM to lead the US offensive

Correction: Physitrack Plc: Interim Report Q1 2026 – Stable Profitability, RTM Launch and a New Chapter for North American Expansion

Redeye: Physitrack (Q1 Initial take): Results close to expectations; RTM and US listing in focus

Physitrack Plc: Delårsrapport Q1 2026 – Stabil lönsamhet, RTM-lansering och ett nytt kapitel för expansion i Nordamerika

Physitrack Plc: Interim Report Q1 2026 – Stable Profitability, RTM Launch and a New Chapter for North American Expansion

Physitrack Plc: Notice of Annual General Meeting

Invitation to Physitrack PLC Q1 2026 interim report webcast conference

Physitrack PLC receives lender consent for share buyback program

Redeye: Physitrack (Q1 Preview): Focus on margin resilience and growth inflection

Physitrack: Champion Health in New Agreement with UK Enterprise Employer

Physitrack signs Agreement with New York-based Academic Medical Center

Physitrack announces CHF 150,000 deal with Swiss care provider

Physitrack PLC Publishes 2025 Audited Annual Report

Redeye: Physitrack (Interview): Paving the way to accelerate growth in 2026

Physitrack announces agreement with leading Swiss healthcare organisation

Physitrack Plc Announces Update on Publication of Annual Report

Redeye: Physitrack (Q4 Review): Strategic reset complete; pivot to pure-SaaS growth acceleration

Physitrack Plc: Bokslutskommuniké Q4 och helåret 2025 – Förbättrad lönsamhet och fortsatt positivt kassaflöde

Physitrack Plc: Year-end report Q4 and full year 2025 – Improved profitability and sustained positive cash flow

Physitrack PLC announces intention to implement share buyback program

Invitation to Physitrack PLC Q4 2025 interim report webcast conference

Physitrack PLC Announces Change of Annual General Meeting Date

First North Stockholm

Physitrack operates in the healthcare sector and specializes in physiotherapy. The product portfolio includes digital healthcare offerings for companies via SaaS solutions. In addition to the main business, personal service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe and North America. Physitrack was founded in 2012 and is headquartered in London.

The journey continues in the same direction after a good Q2. Profitability and cash flow are developing, and the closure of low-margin clinics reduces revenue as expected. One-off restructuring costs are still visible, of course. One-off costs out of the figures going forward and a couple of bigger deals on the Wellness side, then there will be good grounds for a re-rating of the valuation  Full report:            storage.mfn.se              q3-2025-interim-report-final.pdf                             Physitrack PLC – Interim report: January – September 2025   Summary for the period  Third quarter: 1st July – 30th September 2025 Based on Alternative Key Performance Measures, the Company’s key financial highlights for the period are summarised below. Performance broken down per division is provided later in this release.   Pro forma revenue, following planned low margin revenue reduction, has increased by 6 per cent to generate total sales of EUR 3.5m (EUR 3.3m). This grew by 9 per cent on a constant currency basis.   Lifecare achieved a 13 per cent revenue increase, reaching EUR 2.9m. When assessing organic revenue free from currency fluctuations this was a 17 per cent revenue increase, reaching EUR 3.0m.   Wellness revenue declined by 18 per cent on a pro forma revenue basis to EUR 0.6m. On a constant currency basis, revenue declined by 16 per cent. This is a reflection of unprofitable clinic closures as well as planned expiry of legacy founder-linked contracts as the division refocuses on higher margin enterprise customers.   Subscription revenue increased 7 per cent (EUR 0.2m) to EUR 3.0m and now makes up 88 per cent of total group revenue, an increase from 82 at Q3 2024.   Adjusted EBITDA of EUR 1.2m (EUR 0.9m) was generated resulting in a Pro forma adjusted EBITDA margin of 33 per cent (28 per cent).   Pro forma adjusted EBITDA less CAPEX of EUR 0.4m (EUR 0.1m) was generated resulting in an Pro forma adjusted EBITDA margin less CAPEX margin of 11 per cent (2 per cent). This was split between Lifecare of EUR 0.7m / 23 per cent margin and Wellness of EUR -0.04m / -7 per cent margin.   Adjusted operating loss of EUR 0.1m (loss EUR 0.2m) was generated resulting in a margin of -2 per cent (-6 per cent).   Adjusted ordinary and diluted profit per share totalled EUR -0.01 (EUR (0.02)).   Cashflow generated from operations before the payment of adjusting items equalled EUR 1.4m (EUR 0.8m).   Free cash flow for the quarter was a net inflow of EUR 0.4m (outflow EUR 0.4m).    Edit: Adding Redeye’s quick comments here; according to them, it also met expectations.                   redeye.se              Physitrack (Q3 Initital take): Stable quarter with continued margin expansion...    Redeye sees a Q3 report from Physitrack largely in line with our expectations. The company continues to execute well on its margin expansion path, generating solid free cash flow. We are not too conc

Stable            storage.mfn.se              q1-2026-interim-report-v1.pdf                              Summary for the period First quarter: 1 January – 31 March 2026 Based on Alternative Key Performance Measures, the Company’s key financial highlights for the period are summarised below.  Constant currency revenue amounted to EUR 3.3m (EUR 3.1m), corresponding to 6 per cent year-on-year growth. Subscription revenue continued to represent the majority of Group revenue (96 per cent), reflecting the strength of the recurring SaaS model. Adjusted EBITDA decreased 3 per cent maintaining at EUR 1.1m (EUR 1.1m), corresponding to a margin of 34 per cent (36 per cent). Adjusted EBITDA less CapEx decreases to EUR 0.3m (EUR 0.5m). Operating cash flow from continuing operations maintained at a relatively consistent level EUR 0.9m (EUR 1.0m). Free cash flow from continuing operations remained positive at EUR 0.1m (EUR 0.2m), maintaining 6 consecutive quarters of positive free cash flow.   Interesting highlight, listing on the US OTC market   A further development is our ongoing review of a potential quotation on the OTCQX Best Market in the United States. This could enhance access to US investors without affecting our Nasdaq First North Premier listing or involving a capital raise, supporting our continued expansion in North America.

Permission received from the lender to start the program  Physitrack PLC receives lender consent for share buyback program Physitrack PLC (Nasdaq First North: PTRK) (“Physitrack” or the “Company”) today announces that it has received the necessary consent from its banking partner to proceed with its previously announced share buyback program (the “SBB”), removing the final material condition to implementation. The SBB will be subject to an annual cap and will incorporate standard governance controls, including pause triggers and resumption conditions appropriate for a program of this nature. All repurchases will be conducted in accordance with the safe harbour provisions of EU Market Abuse Regulation (MAR) Article 5 and Nasdaq First North Premier Growth Market requirements. Henrik Molin, CEO and co-founder, commented: “Receiving bank approval is an important milestone. All material conditions to the program are now in place and we look forward to updating shareholders further in due course as we appoint a broker for the execution of the program.”

US market is open   While not significant in value, the signal value for the future is very good.  Physitrack signs Agreement with New York-based Academic Medical Center Physitrack PLC (Nasdaq First North Premier: PTRK) — New Commercial Agreement Generates $100,556 in Total Contract Value and $31,897 in Annual Recurring Revenue with major North American Customer. NEW YORK, United States, and LONDON, United Kingdom, March 30, 2026 Physitrack today announced a new commercial agreement with a New York state-based academic medical center to deliver the Physitrack platform. The agreement is valued at $100,556 in total contract value and $31,897 in annual recurring subscription revenue, with revenue recognition expected to commence in Q2 2026. Subsequent phases of the agreement may include expanded scope and additional user licenses, with the potential to generate additional recurring revenue. Under the agreement, Physitrack will provide its digital rehabilitation and clinical exercise prescription platform to 190 clinician users, enabling the customer to:  Improve access to rehabilitation care and remote patient monitoring across clinical teams Scale digital home exercise programme delivery and patient education through a single integrated platform Enhance clinical outcomes tracking and patient engagement through integrated telehealth capabilities

I would hope for more deals on the wellness side so that its competitiveness and demand would be proven. This will do for now while waiting for those   Physitrack announces agreement with leading Swiss healthcare organisation Physitrack PLC (Nasdaq First North Premier: PTRK) has reached an agreement with a major Swiss Health Care organisation. The deal is worth 149,985 CHF (approximately 156,000 EUR), equivalent to 37,497 CHF (approximately 39,000 EUR) in annual recurring subscription revenue (ARR)             storage.mfn.se              physitrack-announces-agreement-with-leading-swiss-healthcare-organisation.pdf

A Q4 update fairly in line with expectations. Official and audited figures will follow later. Growth is needed; profitability is significantly better.            storage.mfn.se              pdf-report-physitrack-plc-unaudited-fy2025-trading-update-and-preliminary-results.pdf                             CEO Henrik’s interview  https://vimeo.com/1159117322/60b2488cb7?fl=tl&fe=ec Here is a good summary from an active follower, especially the notes regarding the US market.  https://x.com/HappyZubi/status/2015730831482916923?s=20 edit:  Adding Redeye’s comments as well:                   redeye.se              Physitrack (Q4 preliminary figures): Margins improving, but growth stalled    Physitrack released preliminary Q4 2025 figures this morning, which were broadly in line with our expectations. The main highlights include continued margin expansion and improved free cash flow (FCF

Redeye’s more extensive comments                   redeye.se              Physitrack (Q3 Review): Staying on track with solid profitability and cash flow    Redeye has updated its estimates following Physitrack’s Q3 2025 report, which was broadly in line with expectations. The quarter showed continued margin strength and solid cash flow generation, with                             And OT Analytics’ corresponding [analysis]  (a private investor who follows Physitrack and is a major owner)            preview.mailerlite.io              Physitrack | Stabilt, men utan lyft                              In short: as my own comment above. Cash flow and profitability are now in order. Growth is needed on the Wellness side for the true value to emerge. Trades at approx. \~50% discount to peers. Edit 24.10. also adding Lind Research’s analyses here                   Lind Research              Physitrack (PTRK): Market Misses the Cash-Flow and SaaS Quality Shift -...    Physitrack’s Q3 confirmed steady progress in its SaaS transition, with EBITDA up 25% and free cash flow turning positive for a fourth consecutive quarter. Lifecare remains the core profit driver, growing ARR 13% YoY and delivering sector-leading...

Physitrack

8.78 SEK

+1.39 %